Molecular Response of Chronic Myeloid Leukaemia Patients to Tyrosine Kinase Inhibitors

Background: The goal of therapy in Chronic Myeloid Leukaemia (CML) with tyrosine kinase inhibitors (TKIs) has been to achieve the molecular responses, as measured by the reduction or elimination of BCR-ABLl transcript. Objective: The aim of the study is to observe the molecular response status of CM...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Md. Imran Hossain, Md. Jaki Yamani, Md. Golzar Hossain, Mohammed Murad Hossain, Md. Rafiquzzaman Khan, Md. Abdul Aziz
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Haematology Society of Bangladesh 2020-05-01
Saila:	Haematology Journal of Bangladesh
Gaiak:	Ph chromosome CML BCR-ABL1 fusion gene tyrosine kinase inhibitors RQ-PCR minimal residual disease
Sarrera elektronikoa:	https://journal.hematologybd.org/index.php/haematoljbd/article/view/42
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!